Business
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
PARIS, May 13, 2025--Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, took place on May 13, 2025, at 2:00 pm CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting was chaired by Laurence
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/09d4bf93ab9c5b6d8e699e7b6eb7fbbc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9x7r41InZ75lZdPuDPvU0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/09d4bf93ab9c5b6d8e699e7b6eb7fbbc","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, May 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, took place on May 13, 2025, at 2:00 pm CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting was chaired by Laurence Rodriguez, Chief Executive Officer of the Company.","length":513,"tagName":"p"},{"type":"text","content":"All resolutions recommended by the Board of Directors and submitted to the Combined General Meeting were adopted, with the exception of Resolution A, which was rejected, in accordance with the recommendations of the Board. The quorum on first convening amounted to 56.51%.","length":272,"tagName":"p"},{"type":"text","content":"During the General Meeting, the Chief Executive Officer reviewed the key achievements of 2024, a year marked by careful cash management, strengthened financial structure with the participation of new investors and renewed support from historical shareholders, as well as the renegotiation of the Company’s financial obligations. She also highlighted progress in manufacturing, including the optimization of GenSight’s technology, preparation for technology transfer to a new manufacturing partner, and the successful mixing and pharmaceutical release of two active substance batches. On the regulatory and clinical fronts, the year saw the preparation of the Phase III RECOVER protocol, the planned submission of the Early Access Program (AAC) application in November 2024, and the continuation of strong scientific communication through international c...